Use of drugs that inhibit the renin-angiotensin-aldosterone system in patients who have survived myocardial infarction – domestic and international registry data
Gottsegen György Országos Kardiológiai Intézet, Nemzeti Infarktus Regiszter, Budapest
Referring to data from the National Myocardial Infarction Registry, the author finds that the system of acute care for patients treated for myocardial infarction significantly improved the early prognosis of patients with myocardial infarction. Still, the 1-year mortality rate is unfavourable due to deficiencies in secondary prevention. Currently, of the activities/interventions included in the concept of secondary prevention, only data are available for pharmacotherapy that has been shown to have a positive effect on survival. In the present compilation, the author examines the frequency of medication that inhibits the renin-angiotensin-aldosterone system (RAAS) among the drugs recommended for hospital discharge of 32,057 patients treated for infarction and compares it with international data. In Hungary, 84.4% of patients received RAAS inhibitor treatment on hospital discharge, and 93.3% of this patient group received angiotensin-converting enzyme inhibitor-type medication. In international comparison, this ratio is similar to the value reported by the SWEDEHEART Register (84.6%). RAAS inhibitor treatment for both types of infarction is used in Hungary and Sweden at a higher rate than in Estonia (78%) and Norway (61%). The Hungarian and Swedish practice complies with the international recommendation.